OPKO Health, Inc. (OPK) is a global biotherapeutics and diagnostics company focused on the establishment of industry-leading positions in rapidly growing markets. The company leverages its marketing proficiency and innovative and exclusive technologies
The price of OPK stock in regular trades on February 24, 2022, was $3.23 with an increase of 8.39%. The stock decelerated by 13.6% at the last check in the premarket on February 25, 2022,
OPK: Key Financials
On February 24, 2022, OPK released its financials for three months, and the fourth quarter ended December 31, 2021. Some of the crucial points are discussed below.
Revenue
Revenue in Q4 2021 was observed to be $401.3 million versus $494.6 million in the fourth quarter of 2020. The company observed a decrease of $93.3 million in revenue year-over-year.
EPS
Basic and diluted net loss in the fourth quarter of 2021 was $73.8 million or $0.11 per share versus a net income of $32.3 million, or $0.05 per share in the same period of 2020. The company observed a decline in its earnings over the year.
OPK: Events and Happenings
On February 15, 2022, OPK updated the grant of marketing approval for the NGENLA or somatrogon by the European Commission. It is used to treat children from 3 years of age with growth disorder due to inadequate growth hormone secretion. On February 03, 2022, OPK reported that Vifor Fresenius Medical Care Renal Pharma had begun the commercial-scale launch of RAYALDEE in Germany.
On January 21, 2022, OPK announced the issuance of a Complete Response Letter by the FDA for the Biologics License Application for somatrogon. Pfizer assessed the agency’s comments and will work with it to determine a suitable path forward. On January 20, 2022, OPK and Pfizer Japan Inc. informed that NGENLA Injection 24 and 60 mg Pens, had been authorized by the Japanese Ministry of Health, Labor, and Welfare.
On January 18, 2022, OPK and Sema4 updated on their entry into a definitive contract for Sema4 to purchase OPK’s subsidiary, GeneDx, Inc. On January 5, 2022, OPK reported its management’s presence at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10-13, 2022.
Conclusion
OPK stock is 26% down the past year. The company’s stock again declined in Friday’s premarket session as it announced its financials. The company’s financials observed a decline in its revenue and EPS over the year. For the upcoming quarter, the company’s revenue guidance is $317.2 million and EPS is -$0.02.
